GC Cell Corporation (KOSDAQ:144510)

Market Cap	365.91B -1.2%
Revenue (ttm)	170.13B -7.7%
Net Income	-98.19B
EPS	-6,534.81
Shares Out	15.03M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	53,285
Average Volume	74,919
Open	24,850
Previous Close	25,400
Day's Range	23,850 - 24,850
52-Week Range	16,940 - 28,450
Beta	0.72
RSI	47.04
Earnings Date	Feb 6, 2026

About GC Cell

GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in November 2021. GC Cell Corporation was founded in 2011 and is based in Yongin-si, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Employees: 698
• Stock Exchange: KOSDAQ
• Ticker Symbol: 144510

Financial Performance

In 2024, GC Cell's revenue was 174.45 billion, a decrease of -6.98% compared to the previous year's 187.54 billion. Losses were -73.90 billion, 42368.9% more than in 2023.